The effect of sulfasalazine on bovine endothelial cell proliferation and cell cycle phase distribution. Comparison with olsalazine, 5-aminosalicylic acid, and sulfapyridine.
Sulfasalazine is used in the treatment of chronic inflammatory states, for example, in inflammatory bowel disease and to a lesser degree in rheumatoid arthritis. In chronic inflammation, the formation of new blood vessels may play a key role in maintaining the inflammatory state. This process is dependent on the activation and proliferation of the endothelial cells. To investigate the possible role of sulfasalazine and its metabolites, sulfapyridine and 5-aminosalicylic acid, we examined the effect of these drugs on vascular endothelial cell proliferation in vitro. Cultures of bovine aortic endothelial cells were incubated with sulfasalazine and its metabolites. At 24 hours of incubation, sulfasalazine inhibited tritiated thymidine incorporation and cell proliferation and had already slowed S-phase progression at a concentration greater than 0.125 mmol/L. After 3 hours of incubation, sulfasalazine inhibition of tritiated thymidine incorporation into the DNA of endothelial cells was observed. This inhibition was completely reversible 24 hours after the drug was removed. One of the possible mechanisms for the inhibition of endothelial cell proliferation is interference with the de novo synthesis of thymidine that depends on folate-dependent enzymes. The effect of deoxyuridine and tetrahydrofolate on tritiated thymidine incorporation into cellular DNA, as well as release of tritium to water by [5-3H]-labeled deoxyuridine on methylation to thymidine, were used as probes for the de novo synthesis of thymidine. Deoxyuridine and tetrahydrofolate, when added to cells either individually or together for 3 hours, suppressed incorporation of tritiated thymidine into DNA through an increase in de novo thymidine synthesis. Sulfasalazine, but not its metabolites, reduced this suppression.2+ culture is inhibited by sulfasalazine and olsalazine but not by their metabolites. This inhibition appears to depend partly on the reduction of de novo synthesis of thymidine that is folate dependent.
Department of Medicine, University of Illinois, Chicago.
P
P
Sharon
E A
EA
Drab
J S
JS
Linder
S W
SW
Weidman
S M
SM
Sabesin
D B
DB
Rubin
D000636:Aminosalicylic Acids / Q000494:pharmacology; D000818:Animals; D002417:Cattle; D002452:Cell Count / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects*; D003857:Deoxyuridine / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology*; D019804:Mesalamine; D013427:Sulfapyridine / Q000494:pharmacology; D012460:Sulfasalazine / Q000494:pharmacology*; D013763:Tetrahydrofolates / Q000494:pharmacology; D013936:Thymidine / Q000037:antagonists & inhibitors / Q000378:metabolism; D013997:Time Factors; D014316:Tritium
D000636:Aminosalicylic Acids; D013763:Tetrahydrofolates; D014316:Tritium; D012460:Sulfasalazine; C030371:5,6,7,8-tetrahydrofolic acid; D019804:Mesalamine; C032587:olsalazine; D013936:Thymidine; D003857:Deoxyuridine; D013427:Sulfapyridine